CHRIS AMOS to Androgen Antagonists
This is a "connection" page, showing publications CHRIS AMOS has written about Androgen Antagonists.
Connection Strength
0.182
-
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018 05 01; 29(5):1235-1248.
Score: 0.134
-
The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access?to Imaging and Treatment of Metastatic Prostate Cancer. Clin Oncol (R Coll Radiol). 2023 10; 35(10):e628-e635.
Score: 0.048